Drug Profile
MEM 1414
Alternative Names: R 1533Latest Information Update: 29 Mar 2010
Price :
$50
*
At a glance
- Originator Memory Pharmaceuticals
- Developer Roche
- Class Antidementias; Antidepressants; Nootropics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma; Alzheimer's disease; Major depressive disorder; Mild cognitive impairment
Most Recent Events
- 29 Mar 2010 No development reported - Phase-I for Alzheimer's disease in USA (PO)
- 29 Mar 2010 No development reported - Phase-I for Mild cognitive impairment in USA (PO)
- 29 Mar 2010 No development reported - Phase-II for Allergic asthma in USA (PO)